7α-Methyl-Nortestosterone (MENT): The Optimal Androgen for Male Contraception

References

• WHO Task Force. Methods for the regulation of male fertility contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990; 336: 955–9
   PubMed Web of Science ®Google Scholar
• Matsumoto A M. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle stimulating hormone, and sperm production. J Clin Endocrinol Metab 1990; 70: 282–7
   PubMed Web of Science ®Google Scholar
• Bagatell C J, McLachlan R I, deKretser D M, et al. Comparison of the suppressive effects of testosterone and a potent new gonadotropin-releasing hormone antagonist on gonadotropin and inhibin levels in normal men. J Clin Endocrinol Metab 1989; 69: 43–8
   PubMedGoogle Scholar
• Bouchard P, Garcia E. Influence of testosterone substitution on sperm suppression by LHRH agonists. Hormone Res 1987; 28: 175–80
   PubMedGoogle Scholar
• Nankin H R. Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril 1987; 47: 1004–9
   PubMed Web of Science ®Google Scholar
• Behre H M, Oberpenning F, Nieschlag E. Comparative pharmacokinetics of androgen preparation: application of computer analysis and simulation. Testosterone: action, deficiency, substitution, E Nieschlag, H M Behre. Springer-Verlag, Berlin 1990; 115–35
   Google Scholar
• Knuth V A, Yeung C H, Nieschlag E. Combination of 19-nortestosterone-hexoxyphenylpropionate (Anadur) and depot-medroxy-progesterone-acetate (DMPA) for male contraception: influence on conventional semen parameters and sperm motion in 12 volunteers. Fertil Steril 1989; 51: 1011–18
   PubMed Web of Science ®Google Scholar
• Behre H M, Nashan D, Hubert W, Nieschlag E. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. J Clin Endocrinol Metab 1992; 74: 84–90
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Behre H M. Pharmacology and clinical use of testosterone. Testosterone: action, deficiency, substitution, E Nieschlag, H M Behre. Springer-Verlag, Berlin 1990; 92–114
   Google Scholar
• Handelsman D J, Conway A J, Boylan L M. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 1990; 71: 216–22
   PubMed Web of Science ®Google Scholar
• Weinbauer G F, Marshall B R, Nieschlag E. New injectable testosterone ester maintains serum testosterone of castrated monkeys in the normal range for four months. Acta Endocrinol 1986; 133: 128–32
   Google Scholar
• Bhasin S, Swerdloff R S, Steiner B, et al. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10–11 weeks in hypogonadal men. J Clin Endocrinol Metab 1992; 74: 75–83
   PubMed Web of Science ®Google Scholar
• Bardin C W, Catterall J F. Testosterone, a major determinant of extragenital sexual dimorphism. Science 1981; 211: 1285–94
   PubMed Web of Science ®Google Scholar
• Agarwal A K, Monder C. In vitro metabolism of 7 α-methyl-19-nortestosterone by rat liver, prostate, and epididymis: Comparison with testosterone and 19-nortestosterone. Endocrinology 1988; 123: 2187–93
   PubMedGoogle Scholar
• Kumar N, Dldolkar A K, Sundaram K, Monder C, Bardln C W. The biological activity of 7α-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 1992; 130: 3677–83
   PubMed Web of Science ®Google Scholar
• Sundaram K, Kelzer-Zucker A, Thau R B, Bardln C W. Reversal of testicular function after prolonged suppression with an LHRH agonist in rhesus monkeys. J Androl 1987; 8: 103–7
   PubMed Web of Science ®Google Scholar
• Brooks J R, Baptista E M, Berman C, et al. Response of rat ventral prostate to a new and novel 5α-reductase inhibitor. Endocrinology 1981; 109: 830–6
   PubMed Web of Science ®Google Scholar
• Biohm T R, Laughlin M E, Benson M D, et al. Pharmacological induction of 5-reductase deficiency in the rat: Separation of testosterone mediated and 5α-dihydrostes-tosterone-mediated effects. Endocrinology 1986; 119: 959–66
   PubMedGoogle Scholar
• Bruchovsky N, Wilson J D. The conversion of testosterone to 5α-androstan-17-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968; 243: 2012–21
   PubMed Web of Science ®Google Scholar
• Liao S, Liang T, Castaneda E, Shao T-C. Steroid structure and androgenic activity. J Biol Chem 1973; 248: 6154–62
   PubMed Web of Science ®Google Scholar
• Peterson R E, Imperato-McGlnley J, Gautier T, Sturla E. Male pseudohermaphroditism due to steroid 5α-reductase deficiency. Am J Med 1977; 62: 177
   Google Scholar